Bristol-Myers Squibb Stock Performance, Earnings Beat, and Analyst Ratings
Princeton-based Bristol-Myers Squibb (BMY) has outperformed both the S&P 500 Index ($SPX) and healthcare sector ETF XLV in recent months. The stock rose nearly 17.9% year-to-date as of July 2026, compared to SPX's 8.5%. On April 30, BMY reported better-than-expected Q1 earnings with revenue rising 2.6% to $11.5 billion and adjusted EPS at $1.58. Analysts expect continued growth for the company in fiscal year 2026, forecasting full-year revenue between $46 billion and $47.5 billion and adjusted EPS of $6.05–$6.35. The consensus rating among analysts remains
Tickers: $BMY
Topics: biotech earnings pharmaceuticals